AtaiBeckley (ATAI) Current Leases (2022 - 2023)

AtaiBeckley (ATAI) posted Current Leases of $292000.0 for Q3 2023, down 9.32% sequentially from $322000.0 in Q2 2023.

Analysis

AtaiBeckley (ATAI) Current Leases (2022 - 2023) Analysis & Trends

AtaiBeckley has reported Current Leases for 2 years, with the latest figure at $292000.0 in Q3 2023.

Quarterly Current Leases changed N/A year-over-year to $292000.0 in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $292000.0 (changed N/A YoY) and the FY2022 annual result came in at $180000.0, changed N/A from the prior year.
Current Leases fell to $292000.0 in Q3 2023 per ATAI's latest filing, from $322000.0 in the prior quarter.
Over five years, Current Leases peaked at $322000.0 in Q2 2023 and troughed at $180000.0 in Q4 2022.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Current Leases (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	720.00 Mn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	11.00 Mn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	-
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	16.75 Mn
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	21.95 Mn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	45.93 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	6.27 Mn
10	AtaiBeckley	1.61 Bn	1.61 Bn	-	-

Historic Data

Download Data